Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity

Aaron DeBono, David R. Thomas, Lindsay Lundberg, Chelsea Pinkham, Ying Cao, J. Dinny Graham, Christine L. Clarke, Kylie M. Wagstaff, Sharon Shechter, Kylene Kehn-Hall, David A. Jans

Research output: Contribution to journalArticleResearchpeer-review

Abstract

There are currently no therapeutics to treat infection with the alphavirus Venezuelan equine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up to 14% of cases. Large outbreaks of VEEV can result in 10,000 s of human cases and mass equine death. We previously showed that mifepristone (RU486) has anti-VEEV activity (EC 50 = 20 μM) and only limited cytotoxicity (CC 50 > 100 μM), but a limitation in its use is its abortifacient activity resulting from its ability to antagonize the progesterone receptor (PR). Here we generate a suite of new mifepristone analogues with enhanced antiviral properties, succeeding in achieving >11-fold improvement in anti-VEEV activity with no detectable increase in toxicity. Importantly, we were able to derive a lead compound with an EC 50 of 7.2 µM and no detectable PR antagonism activity. Finally, based on our SAR analysis we propose avenues for the further development of these analogues as safe and effective anti-VEEV agents.

Original languageEnglish
Article number2634
Number of pages19
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 22 Feb 2019

Keywords

  • medicinal chemistry
  • target validation

Cite this

DeBono, Aaron ; Thomas, David R. ; Lundberg, Lindsay ; Pinkham, Chelsea ; Cao, Ying ; Graham, J. Dinny ; Clarke, Christine L. ; Wagstaff, Kylie M. ; Shechter, Sharon ; Kehn-Hall, Kylene ; Jans, David A. / Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{80fcb33b17ae432795d2388e2408d838,
title = "Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity",
abstract = "There are currently no therapeutics to treat infection with the alphavirus Venezuelan equine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up to 14{\%} of cases. Large outbreaks of VEEV can result in 10,000 s of human cases and mass equine death. We previously showed that mifepristone (RU486) has anti-VEEV activity (EC 50 = 20 μM) and only limited cytotoxicity (CC 50 > 100 μM), but a limitation in its use is its abortifacient activity resulting from its ability to antagonize the progesterone receptor (PR). Here we generate a suite of new mifepristone analogues with enhanced antiviral properties, succeeding in achieving >11-fold improvement in anti-VEEV activity with no detectable increase in toxicity. Importantly, we were able to derive a lead compound with an EC 50 of 7.2 µM and no detectable PR antagonism activity. Finally, based on our SAR analysis we propose avenues for the further development of these analogues as safe and effective anti-VEEV agents.",
keywords = "medicinal chemistry, target validation",
author = "Aaron DeBono and Thomas, {David R.} and Lindsay Lundberg and Chelsea Pinkham and Ying Cao and Graham, {J. Dinny} and Clarke, {Christine L.} and Wagstaff, {Kylie M.} and Sharon Shechter and Kylene Kehn-Hall and Jans, {David A.}",
year = "2019",
month = "2",
day = "22",
doi = "10.1038/s41598-019-38671-y",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. / DeBono, Aaron; Thomas, David R.; Lundberg, Lindsay; Pinkham, Chelsea; Cao, Ying; Graham, J. Dinny; Clarke, Christine L.; Wagstaff, Kylie M.; Shechter, Sharon; Kehn-Hall, Kylene; Jans, David A.

In: Scientific Reports, Vol. 9, No. 1, 2634, 22.02.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity

AU - DeBono, Aaron

AU - Thomas, David R.

AU - Lundberg, Lindsay

AU - Pinkham, Chelsea

AU - Cao, Ying

AU - Graham, J. Dinny

AU - Clarke, Christine L.

AU - Wagstaff, Kylie M.

AU - Shechter, Sharon

AU - Kehn-Hall, Kylene

AU - Jans, David A.

PY - 2019/2/22

Y1 - 2019/2/22

N2 - There are currently no therapeutics to treat infection with the alphavirus Venezuelan equine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up to 14% of cases. Large outbreaks of VEEV can result in 10,000 s of human cases and mass equine death. We previously showed that mifepristone (RU486) has anti-VEEV activity (EC 50 = 20 μM) and only limited cytotoxicity (CC 50 > 100 μM), but a limitation in its use is its abortifacient activity resulting from its ability to antagonize the progesterone receptor (PR). Here we generate a suite of new mifepristone analogues with enhanced antiviral properties, succeeding in achieving >11-fold improvement in anti-VEEV activity with no detectable increase in toxicity. Importantly, we were able to derive a lead compound with an EC 50 of 7.2 µM and no detectable PR antagonism activity. Finally, based on our SAR analysis we propose avenues for the further development of these analogues as safe and effective anti-VEEV agents.

AB - There are currently no therapeutics to treat infection with the alphavirus Venezuelan equine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up to 14% of cases. Large outbreaks of VEEV can result in 10,000 s of human cases and mass equine death. We previously showed that mifepristone (RU486) has anti-VEEV activity (EC 50 = 20 μM) and only limited cytotoxicity (CC 50 > 100 μM), but a limitation in its use is its abortifacient activity resulting from its ability to antagonize the progesterone receptor (PR). Here we generate a suite of new mifepristone analogues with enhanced antiviral properties, succeeding in achieving >11-fold improvement in anti-VEEV activity with no detectable increase in toxicity. Importantly, we were able to derive a lead compound with an EC 50 of 7.2 µM and no detectable PR antagonism activity. Finally, based on our SAR analysis we propose avenues for the further development of these analogues as safe and effective anti-VEEV agents.

KW - medicinal chemistry

KW - target validation

UR - http://www.scopus.com/inward/record.url?scp=85062042783&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-38671-y

DO - 10.1038/s41598-019-38671-y

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2634

ER -